IFNB1 and relapsing-remitting multiple sclerosis: The development of the modern MS treatments begins with IFNβ and glatiramer acetate which were used for the reduction of relapses in relapsing - remitting MS (RRMS) cases 88-91, of white matter lesions development and disability accumulation 92, 93.